A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Conditions: Rhabdoid Tumors; INI1-negative Tumors; Synovial Sarcoma; Malignant Rhabdoid Tumor of OvaryIntervention: Drug: TazemetostatSponsor: Epizyme, Inc.Not yet recruiting - verified November 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials